bladder cancer

Urology Product Preview May 2014Drugs and devices in the pipeline from MEI Pharma, Bayer HealthCare, Merck, Pfizer, and Minomic International.
Growth factor inhibition shows promise in bladder CaPreliminary studies suggest that inhibition of fibroblast growth factor receptors (FGFR) 1, 2, 3, and 4 may be a promising approach for the treatment of bladder cancers and other cancers that harbor FGFR alterations.
Gene set breaks high-grade bladder cancer into two subtypesResearchers at the University of North Carolina School of Medicine, Chapel Hill, have identified a discrete set of genes that segregate high-grade bladder cancer into two distinct subtypes—basal-like and luminal—each of which appears to have its own molecular characteristics and outcome. The authors also found that the two subtypes share many of the characteristics seen in basal and luminal breast cancer subtypes, a discovery with clinical implications.
Bladder cancer study identifies therapeutic targetsA comprehensive molecular characterization of muscle-invasive urothelial bladder carcinoma suggests multiple opportunities for therapeutic intervention.
Bladder cancer study reveals potential drug targetsResearchers from the National Institutes of Health have identified new potential therapeutic targets for muscle-invasive bladder cancer, including important genes and pathways that are disrupted in the disease.
Breast cancer drug may play role in bladder cancerMayo Clinic researchers have found amplification of HER2, a known driver of some breast cancers, in micropapillary urothelial carcinoma and have shown that the presence of HER2 amplification is associated with particularly aggressive tumors.
Nutritional status affects post-cystectomy outcomesPreoperative hypoalbuminemia is a risk factor for complications following radical cystectomy, say researchers from the University of North Carolina, Chapel Hill.
Death, incidence rates of prostate cancer, other GU cancers dropBoth the death rate and incidence rate for prostate cancer continues to decline, according to the latest round of statistics from leading U.S. cancer groups.
Urology Product Preview November 2013Urology drugs and devices in the pipeline from AltheRx Pharmaceuticals, TARIS Biomedical, AstraZeneca, NxThera, NovaBay Pharmaceuticals, and OncoGenex Pharmaceuticals.
Study: RT viable alternative to cystectomyStandard and reduced high-dose volume radiation therapy for muscle-invasive bladder cancer provide similar tumor control and decreased late toxicity when compared to surgery, say the authors of a study from the United Kingdom.